Expert Interview
A Second Look: Discussing the potential of sibeprenlimab from Otsuka Pharmaceutical and the data from the Phase 3 Visionary Study for IgA Nephropathy (IgAN)
Ticker(s): OTSKYInstitution: University of Pittsburgh Medical Center Nephrology Network
- Nephrologist at UPMC Medical Network
- Manages 400 Chronic Kidney Disease patients with high CRP
- Special focus in CKD and Acute Renal Failure
How many patients with IgAN do you manage?
Added By: ben_adminWhere would sibeprenlimab fit into your treatment approach for IgAN?
Added By: ben_adminHow does sibeprenlimab compare to other APRIL inhibitory agents?
Added By: ben_adminWhat are your thoughts on the safety profile of sibeprenlimab for treating IgA nephropathy?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
